Medifast, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MED research report →
Range $12 – $12
Price Chart
About the company
Medifast, Inc. , through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the Asia-Pacific region.
- CEO
- Nicholas Johnson
- IPO
- 1993
- Employees
- 380
- HQ
- Baltimore, MD, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive recovery phase, trading above its 50-day and 200-day moving averages after a long base. It sits near the top of its 52-week range, which points to improving momentum, though the move still needs follow-through to confirm a durable trend.
Street sentiment is cautious but stable, with a Hold consensus and a $12 target versus a last close above that level. Recent target work has trended lower, including a cut to $12 from $15, suggesting analysts still see limited upside despite the rebound.
Earnings have been a beat-heavy story, with 6 of the last 8 quarters topping estimates. The next setup is still negative, with 2026 EPS estimated at -0.86 and 2027 at -0.04, so shareholders should watch whether losses keep narrowing and revenue stabilizes.
Insider activity leans constructive, driven by repeated discretionary buying from director Kiai Parsa and two discretionary sales from director Chard Daniel R. The buying has been larger and more frequent than the selling, which supports confidence, though the sales keep the signal from being one-sided.
Profitability remains weak, with a -11.6% operating margin and -13.6% net margin, but gross margin is still a solid 69.2%. Cash generation is a bright spot: free cash flow was $12.5 million, and the balance sheet shows $167.3 million of cash against $10.7 million of debt.
MED screens as a niche, coach-led weight-loss name rather than a broad consumer staple, so its valuation is more tied to turnaround execution than category multiples. The stock trades with a modest beta of 0.687, which fits a lower-volatility profile, but the market is still pricing in a challenged growth path.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $131.40M
- P/E
- -3.31
- PEG
- 0.00
- P/S
- 0.46
- P/B
- 0.76
- EV/EBITDA
- -5.26
- Div Yield
- 0.00%
- Gross Margin
- 69.21%
- Op Margin
- -10.88%
- Net Margin
- -13.64%
- ROE
- -21.13%
- ROIC
- -16.21%
Latest fiscal year · YoY change
- Revenue
- $385.79M-36.0%
- Gross Profit
- $275.19M-38.1%
- Op Income
- $-14,213,000
- Net Income
- $-18,672,000-993.0%
- EPS
- $-1.70-994.7%
- OCF Growth
- -72.0%
- FCF Growth
- -92.7%
- 52W High
- $13.63
- 52W Low
- $9.22
- 50D MA
- $12.13
- 200D MA
- $11.40
- Beta
- 0.69
- RSI (14)
- 39
- Avg Volume
- 122.14K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Medifast said Q3 was an execution quarter with Trilogy rolling out, coach productivity improving, and management still targeting fourth-quarter profitability despite continued coach-count declines.· October 26, 2026
- Q3 revenue was $72 million, down 19.4% year over year, but in line with guidance.
- Active earning coaches fell to about 10.2 thousand from 19.5 thousand a year ago, while revenue per active earning coach rose 54.1% to $7.06 thousand.
- Gross margin was 69.5%, flat year over year; on an adjusted basis gross margin was 71.7%.
- Management highlighted early traction from Trilogy, including 95% of active earning coaches offering the new Reset line in September.
- The company kept its 2026 profit target intact and expects Q4 revenue of $55 million to $75 million and EPS of $0.00 to $0.25.
Third-quarter 2026 revenue was $72 million, down 19.4% year over year. Gross profit was $50 million, down 19.5%, and gross margin was 69.5%, flat versus the prior-year period; adjusted gross profit was $51.7 million with adjusted gross margin of 71.7%. Net loss was $17.5 million, or $1.57 per diluted share, versus a $2.3 million loss, or $0.21 per diluted share, a year ago; on a non-GAAP basis, net loss was $2.1 million, or $0.19 per diluted share. Active earning coaches were approximately 10.2 thousand versus 19.5 thousand in Q3 2025, while average revenue per active earning coach rose 54.1% to $7.06 thousand. For Q4 2026, management guided to revenue of $55 million to $75 million and EPS of $0.00 to $0.25; for full-year 2026, revenue is expected to be $280 million to $300 million, GAAP EPS loss of $1.80 to $2.05, non-GAAP EPS loss of $0.45 to $0.70, adjusted EBITDA excluding interest income of $10 million to $14 million, and Q4 adjusted EBITDA excluding interest income of $2 million to $6 million.
Nicholas Johnson framed the quarter as a rollout and execution period for the company’s 3.0 strategy, centered on Trilogy, new products, an updated compensation plan, and a unified coach training platform. He emphasized that the business is shifting from weight management to metabolic health, with a focus on preserving lean mass and building a differentiated offering around coaching and science. His tone was confident and constructive, repeatedly pointing to stronger coach productivity, early field enthusiasm, and a path to fourth-quarter profitability.
James Maloney focused on the financial reset and the impact of Project Catalyst. He cited $72 million of revenue, $50 million of gross profit, a 69.5% gross margin, $69.4 million of SG&A including $13.8 million of restructuring charges, and a $17.5 million net loss; adjusted EBITDA excluding interest income was $1.9 million. He said the company ended the quarter with $172.5 million in cash equivalents and investments and no debt, and reaffirmed Q4 and full-year guidance while noting further process-improvement and AI-related efficiencies may create additional leverage in 2027.
Analysts focused on the tension between rising coach productivity and a shrinking coach base, asking whether field changes and the new compensation plan were improving engagement. Management said the compensation plan was intentionally designed to favor healthier, more productive executive directors, even if that means fewer active earning coaches near term. Questions also probed GLP-1 competition and customer mix; management said coaches are already discussing GLP-1s with clients, but the conversation is shifting toward quality of weight loss, lean-mass preservation, and long-term metabolic health. On SG&A, management said Catalyst is largely in place, but more process improvement and AI-driven efficiency are still possible in 2027.
The positive case from the call is that Medifast is seeing early signs of stabilization in the business model it wants to build: coach productivity improved for the fourth straight quarter, coach leaders are engaging with Trilogy, and 95% of active earning coaches were already offering the new Reset line in September. Management also reiterated confidence that the company can reach fourth-quarter profitability while maintaining a strong balance sheet with $172.5 million in cash and investments and no debt.
The main risk remains the steep decline in active earning coaches, which management expects to continue in the near term, and revenue was still down 19.4% year over year. Management also acknowledged that GLP-1 adoption is pressuring the traditional weight-loss category, and Q4 guidance is wide, with revenue ranging from $55 million to $75 million. The call suggested improvement is still early, with full recovery in coach count and top-line growth not yet visible.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.5%
- Shares Outstanding
- 11.18M
- Float Shares
- 8.44M
of shares held by institutions
120 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MED, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Renaissance Technologies LLC | 858.51K | ▲ 79.90K |
| Vanguard Group Inc | 711.50K | ▲ 190 |
| Steamboat Capital Partners, LLC | 706.70K | ▼ 891 |
| Blackrock, Inc. | 513.20K | ▲ 143.69K |
| Two Sigma Investments, LP | 481.38K | ▲ 143.22K |
| Vanguard Capital Management LLC | 446.61K | 0 |
| American Century Companies Inc | 439.22K | ▲ 120.31K |
| Charles Schwab Investment Management Inc | 397.00K | ▼ 234.54K |
| Sixth Street Partners Management Company, L.P. | 397.00K | ▲ 397.00K |
| Dimensional Fund Advisors LP | 373.44K | ▲ 10.04K |
| Marshall Wace, Llp | 352.70K | ▲ 111.06K |
| Morgan Stanley | 244.29K | ▼ 48.21K |
Held by 71 ETFs
Biggest fund positions in MED by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | Kiai Parsa | buy | 82,700 |
| Nov 18, 26 | Kiai Parsa | buy | 8,630 |
| Nov 19, 26 | Kiai Parsa | buy | 2,450 |
| Nov 18, 26 | Kiai Parsa | buy | 256 |
| Nov 4, 26 | Kiai Parsa | buy | 661 |
| Oct 28, 26 | Kiai Parsa | buy | 5,399 |
| Oct 28, 26 | Kiai Parsa | buy | 158 |
| Sep 28, 26 | Chard Daniel R | sell | 9,545 |
| Sep 29, 26 | Chard Daniel R | sell | 9,544 |
| Aug 26, 26 | Kiai Parsa | buy | 41,975 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MED coverage
Recent articles, reports, and earnings notes.
No research on MED yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MED report →Can Medifast's Coaching Model Complement GLP-1 Weight-Loss Drugs?
zacks.com · Nov 18
Will Medifast's Metabolic Health Institute Strengthen Its Edge?
zacks.com · Nov 10
Medifast: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 3
Medifast Is Running The Same Playbook, And I Have The Same Concerns
seekingalpha.com · Oct 28
Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises
zacks.com · Oct 27
Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 26
What Medifast (MED) Said on Its Q3 Earnings Call
marketbeat.com · Oct 26
Medifast (MED) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Oct 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 15, 2026 · Live quote · Not investment advice